Next Phase Newsletter

A venture capital firm based the UK invests in early-stage health-tech companies from Seed to Series A/A+ with check sizes ranging from GBP £500k-£3M. The firm is open to global companies but has a bias to UK, Europe and Israel.  
 
The firm invests in digital diagnostics, digital therapeutics and medical devices. The firm is generally indication-agnostic but has a bias to oncology, cardiovascular, mental health, diabetes, women’s health and health AI. 
 
The firm can be a lead or co-investor and typically takes board or observer seats. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A VC firm with offices in US and Asia invests primarily in therapeutics, with a secondary focus in molecular diagnostics and digital health. For those fields, the firm is interested in first-in-class technology approaches and will invest in early companies with great science, from seed to series A. With their expansion to the US, the firm is now open to investing globally. The firm has generally led investments, but is willing to be part of a syndicate as well. The firm’s investments range based on the stage of the company, but will generally be no more than $5M for seed stage and no more than $10M for series A rounds. 
 
Within therapeutics, the firm is open to both subsector and indication as long as the science is breakthrough. The firm is willing to invest earlier in platform technology companies, and will consider such technologies as early as POC stage. For companies with single assets in development, the firm prefers to see at least small animal data. For molecular diagnostics and digital health companies, the firm is opportunistic as well. 
 
Because the firm invests early in companies with breakthrough science, they are willing to help their portfolio companies develop their strategies and operations. With its broad and trustful network with pharma companies, the firm helps portfolio companies’ boost their businesses development activities. The firm will take a board seat after investment if needed to help the company. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A privately held investment firm operating within a family office structure focuses on early-stage investments across multiple sectors, including life sciences and healthcare. The firm’s sweet spot is pre-seed investments but is open to opportunities from Seed to Series A. The firm’s typical check size is $200k USD per round, with a range of $100k USD to $300k USD, and follow-on investments are possible. While the firm typically does not lead funding rounds, they can serve as technical leads and provide memos for co-investors. The firm is open to opportunities globally. 
 
The firm is primarily interested in therapeutics platforms, enabling technologies and tools for scientists, while also open to considering the more asset-focused companies. The firm is indication agnostic, but tends to avoid investing in companies developing products too similar to those in their current portfolio. In terms of development stages, the firm is open to pre-clinical stage assets with some proof of concepts, which doesn’t necessarily need to be in-vivo. While they are open to engaging with companies in the “idea phase”, it might be too early for investment. The firm prefers to invest early and generally considers assets already in the IND phase or companies generating revenue too late. 
 
The firm does not have specific requirements for the management team. The firm prefers technical teams with complementary skill sets, and are coachable and driven. The firm is an active investor and will consider board or observer seats on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A corporate venture arm of a leading global supplier is interested in investing in other areas including health, mobility, and energy and environment. The firm is a co-GP of a fund dedicated to investing in early-stage startups as well as larger growth investments for follow-ons. The firm also has an additional USD $1.5B dedicated to 2030 for both minority growth and majority investing. As the fund is stage-agnostic and is active in early-, mid-, and late-stage, check sizes are flexible and have ranged between USD $500k-60M. The firm has a global mandate but has strong interest in North American companies. 
 
The firm has a deep interest in the medical space. The fund looks at therapeutics, medtech, diagnostics, and digital health. Though the fund is somewhat agnostic to the therapeutic area, they tend to target aging populations. Indications of interest include respiratory diseases, wound care and chronic diseases with its downstream treatment and associated economics, as well other comorbidities that complicate patient treatment such as cancer care, neurology, dementia, and behavioral health conditions. 
 
The firm does not have strict requirements but prefers to lead or co-lead investments and take a board or observer seat at minimum. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm, with a single LP, has offices in the US. The group looks to make growth-stage investments in the form of preferred equity, ranging from $2M-$7M initially, with additional capital reserved for follow-on financings, typically up to $15M over the life of the investment. The firm usually leads rounds, but is also open to syndicating with other investors. The firm looks to do 3-4 deals a year, and invests in U.S. and Canadian companies. Prospective companies may have some business overseas as long as they are headquartered in the U.S. or Canada. 
 
The firm solely invests in healthcare companies, and is open to any healthcare companies that do not require FDA approval for their product/service. Some of the firm’s recent healthcare investments include a predictive and interventive artificial intelligence platform for health plans and risk bearing providers as well as a next generation drug spend savings platform for employers and health plans. 
 
The firm typically looks for growing companies with a run rate of at least $1M or a signed contract that would put them at a $1M run rate. The firm has no strict requirements in terms of management team, and oftentimes works with first-time entrepreneurs. The firm looks to take a board seat along with an investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A healthcare-focused Growth Equity firm currently manages $1 billion and provides $20-100 million of equity capital per company over the life of the investment. With offices in Boston and London, the firm is primarily looking for companies throughout North America and Europe. 
 
The firm is currently interested in companies in areas of medical technology, biopharmaceuticals, diagnostics, medical devices, life sciences tools, digital health, and veterinary medicine. Significant emphasis is placed on the clinical utility and health economics of potential investments. The firm focuses on later-stage opportunities that are already commercialized or are close to commercialization. The firm is open in terms of indications. 
 
The firm looks for management teams that are very willing to work alongside them, and the firm generally looks to take a board seat. The firm is open to investing in both public and privately held companies, is open to a variety of deal structures, and can consider equity investments or buy-out opportunities. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A newly formed subsidiary of a hedge fund is based in the US. The firm is interested in healthcare and data looking to build predictive disease risk models and has dedicated USD $20M to make investments to early-stage startups in Pre-Seed to Series A rounds. Initial check sizes can go up to USD $2M and the firm can lead or co-invest. The firm does not have geographical restrictions, however, prefers the U.S. and Europe. 
 
The firm is interested in diagnostics and health-tech companies. Specifically, the firm would like to see technologies that allow people to understand and quantify their health including, but not limited to, technologies that help analyze health data, applications and algorithms, mobile applications, and technologies that cater to the medical community to increase work efficiency. The firm would like to see a working prototype that is somewhat validated. 
 
The firm may take a board seat on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.